Creative Medical Technology (CELZ) to Release Quarterly Earnings on Friday

Creative Medical Technology (NASDAQ:CELZ) will likely be issuing its results before the market opens on Friday, March 13th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter.

Creative Medical Technology Price Performance

NASDAQ CELZ opened at $1.94 on Wednesday. The company’s 50 day simple moving average is $1.97 and its 200 day simple moving average is $2.68. Creative Medical Technology has a 12 month low of $1.50 and a 12 month high of $6.25. The firm has a market capitalization of $5.01 million, a PE ratio of -0.67 and a beta of 2.09.

Institutional Investors Weigh In On Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC purchased a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 1.17% of Creative Medical Technology as of its most recent SEC filing. Institutional investors own 1.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CELZ. Wall Street Zen lowered shares of Creative Medical Technology from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Creative Medical Technology in a research report on Monday, December 29th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Creative Medical Technology has an average rating of “Reduce”.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.